Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Assessment of treatment routine and outcome for ranolazine in clinical practice as second-line treatment for stable angina pectoris (AP).
Multicenter, prospective, uncontrolled, non-interventional study at 88 sites including internal specialists, cardiologists, pneumologists, angiologists and primary care practices in Austria.
In this study 292 patients receiving ranolazine in the course of routine treatment on top of beta blockers or calcium channel blockers after failure of first-line therapy.
Dosage and symptoms were recorded at two visits (at intervals of 12 weeks), complemented by treatment rationale and disease characteristics at baseline. Disease intensity was quantified by angina symptoms, nitrate use and by Canadian Cardiovascular Society (CCS) grading. Quality of life (QoL) was assessed through a 10-grade scale. Data were analyzed by descriptive statistics.
Ranolazine was prescribed in order to improve exercise capacity (84.3%), reduce symptoms (83.2%) and reduce AP (77.1%). Of the patients 87.3% received the recommended starting dose of 375 mg and subsequent dose changes were reported for 39.8%. The number of AP attacks was reduced from 5.3 ± 4.5 to 0.8 ± 1.3 per week; nitrate use was reduced from 3.4 ± 4.1 to 0.4 ± 0.9 applications per week. Of the patients 94.0% reported improved exercise capacity and 93.7% reduced symptoms. For the majority of patients, the CCS improved from grade II to I and QoL improved accordingly. Of the patients 3 experienced adverse drug reactions and 95.5% continued ranolazine.
In this real-world study, ranolazine was shown to be effective, safe and well tolerable. Symptoms of AP were improved, as illustrated by the reduced number of angina attacks, reduced rate of nitrate use, reduced CCS scores and improved QoL.
EMA. Ranexa: summary of product characteristics. London: European Medicines Agency; 2013.
Scirica BM, Morrow DA, Hod H, Murphy SA, Belardinelli L, Hedgepeth CM, et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation. 2007;116:1647–52. https://doi.org/10.1161/CIRCULATIONAHA.107.724880. CrossRefPubMed
Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, et al. ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;2013(34):2949–3003. https://doi.org/10.1093/eurheartj/eht296. CrossRef
Federation of Austrian Social Insurance Institutions. Amtliche Verlautbarung der österreichischen Sozialversicherung: 71. Änderung des Erstattungskodex. Vienna: Hauptverband der österreichischen Sozialversicherungsträger; 2010.
Pell G. Use and misuse of Likert scales. Med Educ. 2005;39:970. https://doi.org/10.1111/j.1365-2929.2005.02237.x. author reply 971. CrossRefPubMed
Pichler M. Symptomatische stabile Angina pectoris: Epidemiologie, therapeutische Option und innovative Therapieansätze. J Kardiol. 2006;13:4–5.
Alexopoulos D, Kochiadakis G, Afthonidis D, Barbetseas J, Kelembekoglou P, Limberi S, et al. Ranolazine reduces angina frequency and severity and improves quality of life: observational study in patients with chronic angina under ranolazine treatment in Greece (OSCAR-GR). Int J Cardiol. 2016;205:111–6. https://doi.org/10.1016/j.ijcard.2015.10.180. CrossRefPubMed
Diedrichs H, Wollenberg U, Schmerbach K, Limberg R, Schiffhorst G, Zeiher AM. Application of ranozaline in stable angina pectoris therapy (ARETHA): real-world data from an observational study. J Clin Exp Cardiolog. 2015;6:1–6. CrossRef
Chaitman BR, Pepine CJ, Parker JO, Skopal J, Chumakova G, Kuch J, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA. 2004;291:309–16. https://doi.org/10.1001/jama.291.3.309. CrossRefPubMed
Kosiborod M, Arnold SV, Spertus JA, McGuire DK, Li Y, Yue P, et al. Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (type 2 diabetes evaluation of ranolazine in subjects with chronic stable angina). J Am Coll Cardiol. 2013;61:2038–45. https://doi.org/10.1016/j.jacc.2013.02.011. CrossRefPubMed
Lopatin YM, Rosano GMC, Fragasso G, Lopaschuk GD, Seferovic PM, Gowdak LHW, et al. Rationale and benefits of trimetazidine by acting on cardiac metabolism in heart failure. Int J Cardiol. 2016;203:909–15. https://doi.org/10.1016/j.ijcard.2015.11.060. CrossRefPubMed
Ferrari R. A step further with ivabradine: SIGNIFY (Study assessInG the morbidity–mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease). Eur Heart J. 2009;11:D19–D27. CrossRef
IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil In Angina (IONA) randomised trial. Lancet. 2002;359:1269–75. https://doi.org/10.1016/S0140-6736(02)08265-X. CrossRef
Schmutzler H. Nicht-interventionelle Studie „ARETHA“: Anwendung von Ranolazin in der Therapie der stabilen Angina pectoris. Berlin: Berlin-Chemie AG; 2014.
A.T.I. Arzneimittelinformation Berlin. Ranolazin (Ranexa) bei chronisch stabila Angina Pectoris. Arznei Telegr. 2009;40:26–7.
Szwed H, Sadowski Z, Pachocki R, Domzał-Bocheńska M, Szymczak K, Szydłowski Z, et al. The antiischemic effects and tolerability of trimetazidine in coronary diabetic patients. A substudy from TRIMPOL-1. Cardiovasc Drugs Ther. 1999;13:217–22. CrossRef
Fox K, Ford I, Steg PG, Tendera M, Ferrari R. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:807–16. https://doi.org/10.1016/S0140-6736(08)61170-8. CrossRefPubMed
Boden WE, O’Rourke RA, Teo KK, Maron DJ, Hartigan PM, Sedlis SP, et al. Impact of optimal medical therapy with or without percutaneous coronary intervention on long-term cardiovascular end points in patients with stable coronary artery disease (from the COURAGE Trial). Am J Cardiol. 2009;104:1–4. https://doi.org/10.1016/j.amjcard.2009.02.059. CrossRefPubMed
Al-Lamee R, Thompson D, Dehbi H‑M, Sen S, Tang K, Davies J, et al. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. Lancet. 2018;391:31–40. https://doi.org/10.1016/S0140-6736(17)32714-9. CrossRefPubMed
Alexander KP, Weisz G, Prather K, James S, Mark DB, Anstrom KJ, et al. Effects of ranolazine on angina and quality of life after percutaneous coronary intervention with incomplete revascularization: results from the ranolazine for incomplete vessel revascularization (RIVER-PCI) trial. Circulation. 2016;133:39–47. https://doi.org/10.1161/CIRCULATIONAHA.115.019768. CrossRefPubMed
Weisz G, Généreux P, Iñiguez A, Zurakowski A, Shechter M, Alexander KP, et al. Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2016;387:136–45. https://doi.org/10.1016/S0140-6736(15)00459-6. CrossRefPubMed
Mehta PK, Goykhman P, Thomson LEJ, Shufelt C, Wei J, Yang Y, et al. Ranolazine improves angina in women with evidence of myocardial ischemia but no obstructive coronary artery disease. Jacc Cardiovasc Imaging. 2011;4:514–22. https://doi.org/10.1016/j.jcmg.2011.03.007. CrossRefPubMedPubMedCentral
Taqueti VR, Shaw LJ, Cook NR, Murthy VL, Shah NR, Foster CR, et al. Excess cardiovascular risk in women relative to men referred for coronary angiography is associated with severely impaired coronary flow reserve, not obstructive disease. Circulation. 2017;135:566–77. https://doi.org/10.1161/CIRCULATIONAHA.116.023266. CrossRefPubMed
Miles RH, Passman R, Murdock DK. Comparison of effectiveness and safety of ranolazine versus amiodarone for preventing atrial fibrillation after coronary artery bypass grafting. Am J Cardiol. 2011;108:673–6. https://doi.org/10.1016/j.amjcard.2011.04.017. CrossRefPubMed
Morrow DA, Scirica BM, Chaitman BR, McGuire DK, Murphy SA, Karwatowska-Prokopczuk E, et al. Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial. Circulation. 2009;119:2032–9. https://doi.org/10.1161/CIRCULATIONAHA.107.763912. CrossRefPubMed
Sossalla S, Maier LS. Role of ranolazine in angina, heart failure, arrhythmias, and diabetes. Pharmacol Ther. 2012;133:311–23. https://doi.org/10.1016/j.pharmthera.2011.11.003. CrossRefPubMed
Khan SS, Cuttica MJ, Beussink-Nelson L, Kozyleva A, Sanchez C, Mkrdichian H, et al. Effects of ranolazine on exercise capacity, right ventricular indices, and hemodynamic characteristics in pulmonary arterial hypertension: a pilot study. Pulm Circ. 2015;5:547–56. https://doi.org/10.1086/682427. CrossRefPubMedPubMedCentral
Maier LS, Layug B, Karwatowska-Prokopczuk E, Belardinelli L, Lee S, Sander J, et al. RAnoLazIne for the treatment of diastolic heart failure in patients with preserved ejection fraction: the RALI-DHF proof-of-concept study. Jacc Heart Fail. 2013;1:115–22. https://doi.org/10.1016/j.jchf.2012.12.002. CrossRefPubMed
Manolis AJ, Poulimenos LE, Ambrosio G, Kallistratos MS, Lopez-Sendon J, Dechend R, et al. Medical treatment of stable angina: a tailored therapeutic approach. Int J Cardiol. 2016;220:445–53. https://doi.org/10.1016/j.ijcard.2016.06.150. CrossRefPubMed
- Ranolazine: impact on quality of life in patients with stable angina pectoris, results from an observational study in Austria – the ARETHA AT study
Prim. Prof. Dr. Georg Delle-Karth
- Springer Vienna
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II